Tocilizumab  (Synonyms: 托珠单抗; Anti-Human IL6R, Humanized Antibody)

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis^[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)^[4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Tocilizumab (抗人 IL6R，人源化抗体) (1-100 ng/mL；24 小时、48 小时) 以剂量依赖性方式抑制细胞增殖 (生长速率)，HACM 的生长速率几乎完全降低 100 ng/mL tocilizumab^[2]。
Tocilizumab (抗人 IL6R，人源化抗体) (0.001-10，000 μg/mL；2 天) 抑制 Ba/F3-gp130-IL-6R 细胞用 hIL-6 刺激增殖，IC₅₀ 为 13.5 ng/mL^[1]。
Tocilizumab (抗人 IL6R，人源化抗体) (1 μM；6 小时) 在体外降低 STAT3 的磷酸化，与体内 SAS 细胞一致^[3]。
Tocilizumab (抗人 IL6R，人源化抗体) (1-5 μM；24 小时) 用无血清培养基显著降低SAS细胞中VEGF mRNA的表达^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tocilizumab (抗人 IL6R，人源化抗体) (静脉注射；1.0 mg/100 μL；每周两次，三周) 减少注射了 tocilizumab 的小鼠大脑中每个转移灶的体积^[2]。
Tocilizumab (抗人 IL6R，人源化抗体) (腹膜内注射；100 μg/mL，每 48 小时一次；20 天) 抑制 OSCC 进展并抑制肿瘤血管生成^[3]。
br>

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

375823-41-9

液体

Colorless to light yellow

托珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometry analysis of IL-6R expression U937 cells labelling IL-6R with Tocilizumab at 10nM (Red), 20ng/mL of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) were added to block the binding of Fc of antibody to cells respectively. Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

• [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.  [Content Brief]

  [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.  [Content Brief]

  [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.  [Content Brief]

  [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.  [Content Brief]